These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 21727754)
1. Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats. Nakamori F; Naritomi Y; Furutani M; Takamura F; Miura H; Murai H; Terashita S; Teramura T Drug Metab Pharmacokinet; 2011; 26(5):465-73. PubMed ID: 21727754 [TBL] [Abstract][Full Text] [Related]
2. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476 [TBL] [Abstract][Full Text] [Related]
3. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. Soars MG; Burchell B; Riley RJ J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196 [TBL] [Abstract][Full Text] [Related]
4. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Cubitt HE; Houston JB; Galetin A Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618 [TBL] [Abstract][Full Text] [Related]
5. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Gill KL; Houston JB; Galetin A Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465 [TBL] [Abstract][Full Text] [Related]
6. Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE). Gabor-Worwa E; Kowal-Chwast A; Gaud N; Gogola D; Littlewood P; Smoluch M; Brzózka K; Kus K Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):393-403. PubMed ID: 38642299 [TBL] [Abstract][Full Text] [Related]
7. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform. Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289 [TBL] [Abstract][Full Text] [Related]
8. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Nishimuta H; Sato K; Yabuki M; Komuro S Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Ito K; Houston JB Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335 [TBL] [Abstract][Full Text] [Related]
10. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Miners JO; Knights KM; Houston JB; Mackenzie PI Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060 [TBL] [Abstract][Full Text] [Related]
11. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858 [TBL] [Abstract][Full Text] [Related]
12. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Kemp DC; Fan PW; Stevens JC Drug Metab Dispos; 2002 Jun; 30(6):694-700. PubMed ID: 12019197 [TBL] [Abstract][Full Text] [Related]
13. Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. Activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin. Little JM; Lehman PA; Nowell S; Samokyszyn V; Radominska A Drug Metab Dispos; 1997 Jan; 25(1):5-11. PubMed ID: 9010623 [TBL] [Abstract][Full Text] [Related]
14. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406 [TBL] [Abstract][Full Text] [Related]
15. In vitro glucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: a comparison with other species. Ebner T; Schänzle G; Weber W; Sent U; Elliott J J Vet Pharmacol Ther; 2013 Apr; 36(2):154-60. PubMed ID: 22486410 [TBL] [Abstract][Full Text] [Related]
16. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Naritomi Y; Terashita S; Kimura S; Suzuki A; Kagayama A; Sugiyama Y Drug Metab Dispos; 2001 Oct; 29(10):1316-24. PubMed ID: 11560875 [TBL] [Abstract][Full Text] [Related]
17. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Riley RJ; McGinnity DF; Austin RP Drug Metab Dispos; 2005 Sep; 33(9):1304-11. PubMed ID: 15932954 [TBL] [Abstract][Full Text] [Related]
18. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Cubitt HE; Houston JB; Galetin A Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923 [TBL] [Abstract][Full Text] [Related]
19. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499 [TBL] [Abstract][Full Text] [Related]
20. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Boase S; Miners JO Br J Clin Pharmacol; 2002 Nov; 54(5):493-503. PubMed ID: 12445028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]